Literature DB >> 32435403

Screen of Unfocused Libraries Identified Compounds with Direct or Synergistic Antibacterial Activity.

Claudia Mugnaini1, Filomena Sannio2, Antonella Brizzi1, Rosita Del Prete2, Tiziana Simone2, Teresa Ferraro3, Filomena De Luca2, Federico Corelli1, Jean-Denis Docquier2.   

Abstract

Antibiotic resistance is an increasingly important global public health issue, as major opportunistic pathogens are evolving toward multidrug- and pan-drug resistance phenotypes. New antibiotics are thus needed to maintain our ability to treat bacterial infections. According to the WHO, carbapenem-resistant Acinetobacter, Enterobactericaeae, and Pseudomonas are the most critical targets for the development of new antibacterial drugs. An automated phenotypic screen was implemented to screen 634 synthetic compounds obtained in-house for both their direct-acting and synergistic activity. Fourteen percent and 10% of the compounds showed growth inhibition against tested Gram-positive and Gram-negative bacteria, respectively. The most active direct-acting compounds showed a broad-spectrum antibacterial activity, including on some multidrug-resistant clinical isolates. In addition, 47 compounds were identified for their ability to potentiate the activity of other antibiotics. Compounds of three different scaffolds (2-quinolones, phenols, and pyrazoles) showed a strong potentiation of colistin, some being able to revert colistin resistance in Acinetobacter baumannii.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32435403      PMCID: PMC7236257          DOI: 10.1021/acsmedchemlett.9b00674

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.

Authors:  Antonella Brizzi; Maria Grazia Cascio; Vittorio Brizzi; Tiziana Bisogno; Maria Teresa Dinatolo; Adriano Martinelli; Tiziano Tuccinardi; Vincenzo Di Marzo
Journal:  Bioorg Med Chem       Date:  2007-05-31       Impact factor: 3.641

Review 2.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

3.  Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.

Authors:  Serena Pasquini; Maria De Rosa; Valentina Pedani; Claudia Mugnaini; Francesca Guida; Livio Luongo; Maria De Chiaro; Sabatino Maione; Stefania Dragoni; Maria Frosini; Alessia Ligresti; Vincenzo Di Marzo; Federico Corelli
Journal:  J Med Chem       Date:  2011-07-06       Impact factor: 7.446

Review 4.  Eravacycline, a newly approved fluorocycline.

Authors:  Young Ran Lee; Caitlin Elizabeth Burton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-07       Impact factor: 3.267

Review 5.  Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new.

Authors:  Michael Z David; Matthew Dryden; Thomas Gottlieb; Pierre Tattevin; Ian M Gould
Journal:  Int J Antimicrob Agents       Date:  2017-06-27       Impact factor: 5.283

6.  Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.

Authors:  David Corbett; Andrew Wise; Tara Langley; Kirsty Skinner; Emily Trimby; Stephen Birchall; Alain Dorali; Stephanie Sandiford; Jennifer Williams; Peter Warn; Martti Vaara; Troy Lister
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  The fractional inhibitory concentration (FIC) index as a measure of synergy.

Authors:  M J Hall; R F Middleton; D Westmacott
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

8.  New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains.

Authors:  Valentina Guerrini; Maria De Rosa; Serena Pasquini; Claudia Mugnaini; Antonella Brizzi; Anna Maria Cuppone; Gianni Pozzi; Federico Corelli
Journal:  Tuberculosis (Edinb)       Date:  2013-03-22       Impact factor: 3.131

Review 9.  Vancomycin-Resistant Enterococci: Therapeutic Challenges in the 21st Century.

Authors:  William R Miller; Barbara E Murray; Louis B Rice; Cesar A Arias
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

10.  Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.

Authors:  Alessandro Cassini; Liselotte Diaz Högberg; Diamantis Plachouras; Annalisa Quattrocchi; Ana Hoxha; Gunnar Skov Simonsen; Mélanie Colomb-Cotinat; Mirjam E Kretzschmar; Brecht Devleesschauwer; Michele Cecchini; Driss Ait Ouakrim; Tiago Cravo Oliveira; Marc J Struelens; Carl Suetens; Dominique L Monnet
Journal:  Lancet Infect Dis       Date:  2018-11-05       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.